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Diabetes, especially type 2, affects increasing
numbers of people and creates a global threat to
health and life (1). According to the World Health
Organization, after the year 2020, the number of
patients suffering from diabetes will be doubled. In
this disease the irregular distribution of carbonate,
resulting from the insulin deficiency in case of Type
1 diabetes and from insulin resistance in case of
Type 2 diabetes is a characteristic event. The cause
for this injury related to hyperglycemia is the for-
mation of glycated proteins, glucose oxidation, and
increased level of free fatty acids (2). This results in
oxidative stress in the cells, as well as activation of
oxidative and inflammatory signalling pathways,
which continue to damage the insulin-diarrhoea pro-
ducing cells, what leads eventually to various com-
plications of diabetes. 
At present, the basic aim of the research is to
identify and understand the exact mechanisms of the
development of diabetes. The pancreas is a large
gland located behind the stomach and next to the
gallbladder. It produces digestive enzymes and hor-
mones, including insulin and glucagon that help to
regulate bloodís sugar levels. It was also shown that
the levels of indicators of oxidative stress firstly
increase and then decrease after antioxidants supple-
mentation (2). This suggests that chronic pancreati-
tis (CP) must involve a state of heightened free rad-
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ical mediated injury, and that damage apparently
can be inversed in many people with antioxidant
supplements. CP is a progressive inflammatory dis-
ease, that can lead to a loss of the function of the
pancreas. As a result, people with CP can lose too
much weight, suffer frequent diarrhoea, and devel-
opment of diabetes or vitamin deficiencies. Patients
with exocrine pancreatic insufficiency are at a
greater risk of developing trace-element deficiencies
as a result of malabsorption than patients with
exocrine pancreatic sufficiency (1ñ3).
Dietary supplementation with micronutrients
may be a complement to classical therapies for pre-
venting and treating diabetic complications.
Supplementation is expected to be more effective
when a deficiency in these micronutrients exists.
Some vitamins, such as vitamins E, C, and A and the
carotenoids as well as trace elements such as seleni-
um and zinc, have antioxidant properties (4). In dia-
betes, cells and tissues are damaged due to the imbal-
ance between the production and the removal of free
radicals. The effective biologic antioxidants for
oxidative stress, such as α-lipoic acid, vitamin E and
selenium, are effective in diminishing oxidative dam-
age like membrane lipid peroxidation (5). However,
zinc is involved in a multitude of these processes
within the pancreas, including glucagon secretion,
digestive enzyme activity, and insulin packaging,
secretion and signalling. As a result of this extensive
physiological contribution, deregulations of Zn
metabolism within the pancreas impairs a multitude
of key processes, including glycemic control (6, 7). 
The prevalence of lower plasma concentrations
of trace elements in patients with CP has been
reported (5). Diabetes mellitus is also associated
with deficiencies of vitamins and trace elements,
particularly those of vitamin C (9ñ11), vitamin E
(12) and zinc (5, 13, 14). The concentration of glu-
cose is the most important physiological factor reg-
ulating the secretion of insulin in the blood flowing
from pancreatic β cells. 
The concentration of glucose in the blood
influences both the secretion and the biosynthesis of
that hormone. Simultaneously, insulin increases the
activity of proteins transporting glucose (GLUT4)
into the cell. This is connected with the glucose
membrane receptor stimulation, which in turn
affects the increase of the ATP amount in those
cells. Numerous investigations of the activity of the
vanadium complexes have shown promising results
with regard to their potential use in medical care
(15ñ17).
Vanadium is an element, which occurs in liv-
ing organisms in trace amounts but it may still influ-
ence the metabolism of carbohydrates, lipids and
cholesterol. Nevertheless, the exceeded level of this
element is toxic. Anti-cancer/anti-carcinogen prop-
erty of this element has also been noted (18).
Tolman et al. (19) demonstrated insulin-
mimetic properties of the vanadium salts in vitro.
This study has shown that various vanadium salts,
similarly as insulin, stimulate the transportation and
oxidation of glucose in adipocytes, increase the
glycogen synthesis in the rat diaphragm and hepato-
cytes, and inhibit gluconeogenesis (GNG). The
research conducted by Heyliger et al. (20) demon-
strated that as a result of sodium vanadate treatment
in the animal diabetes model, the normalization of
the glucose level in the hyperglycemia conditions
was achieved. It led to further research on the possi-
bility of application of various vanadium com-
pounds in the treatment of people with the Type 1 or
Type 2 diabetes (21, 22).
Vanadium concentration in the blood of mam-
mals is about 0.2ñ0.5 ng/mL, out of which nearly
80% is present in plasma, as a component of pro-
teins such as transferrin and albumins (23). As the
role of vanadium has not been explained yet, it
seems justified to study the impact of vanadium
compounds on oxidative stress.
Vanadium ions in body fluids are mainly pres-
ent in the form of pentavalent metavanadium, while
the compounds of this element at the fourth oxida-
tion level show intra-cellular domination.
Vanadium ions enter the cell via the anion
canals, where their reduction takes place, primarily
in the presence of glutathione, catechol, cysteine,
NADH, NADPH and L-ascorbic acid (24).
MATERIALS AND METHODS
Material and methods of the experiment were
described in earlier publications (25, 26). 
Animals and vanadium administration
Male Wistar rats weighing between 220ñ250 g
were adapted to a 12 h/12 h day/night cycle, (day
was from 8 a.m. to 8 p.m.) with humidity ranging
between 75ñ85%. The animals were divided into 7
groups of 6 animals in each group. The animals from
each group were housed in two cages (3 rats in
each). After 3 days from the beginning of the exper-
iment, 55 mg of streptozotocin in citric buffer (0.1
mol/L) solution per 1 kg of body mass was injected
into the caudal vein in the volume of 1 mL/kg of
body mass in all groups of animals. Three days sub-
sequent to the injections, the level of glucose was
measured using Exac Tech (Medisense) strip glu-
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cometer. The glucose level measured in animal
blood was higher than 17 mmol/L. After the meas-
urement, the rats were separated into the following
tested groups, diabetic control rats (D), diabetic rats
treated with insulin (Di), 5 groups of diabetic rats
treated with both insulin and tested complexes (Di
1ñ5). The water solutions of tested vanadium com-
plexes were administered once a day before 10 a.m.
by gavage in a dose of 50 µmol/kg and 1 U/kg of
insulin was injected subcutaneously. Five weeks
after the beginning of the the treatment, the rats were
anesthetized (using thiopental 50 mg/kg) and then,
the pancreas was collected. The organ was kept
frozen in ñ20OC until the time of the analysis. 
Synthesis of vanadium complexes 
The complexes Na[VVO(O2)2(2,2í-bpy)] ◊ 8
H2O (complex 1), Na[VVO(O2)2(1,10í-phen)] ◊ 5
H2O (complex 2), Na[VVO(O2)2(4,4í-Me-2,2í-bpy)]
◊ 8 H2O (complex 3), [VIVO(SO4)(1,10í-phen)] ◊ 2
H2O, (complex 4), [VIVO(SO4)(2,2í-bpy)] ◊ H2O
(complex 5), where: 2,2í-bpy = 2,2í-bipyridine,
1,10í-phen = 1,10í-phenanthroline, 4,4í-Me-2,2í-
bpy = 4,4í-dimethyl-2,2í-bipyridine were synthe-
sized using methods described in the literature and
their purity was confirmed by microanalysis and IR
spectroscopy (27ñ29).
Pancreas tissue preparation
Frozen pancreas tissue was transferred directly
to the lyophilizing cabinet and lyophilized using
ABCONO FREEZONE 4,5. in the temperature from
ñ40OC to ñ53OC, and under pressure of 14 Pa to 1 Pa.
Then, the lyophilized organs were homogenized and
pressed into pellets, about 1 mm thickness and 10
mm in diameter, under the pressure of 15 MPa. Such
pellets were placed on Scotch tape and attached to
an aluminum frame.
PIXE analysis
The PIXE (Proton Induced X-ray Emission)
analysis was performed at the Institute of Nuclear
Physics Polish Academy of Sciences (IFJ PAN) in
KrakÛw (30). A multi-elemental probing was car-
ried out using a 2 MeV proton beam (about 0.5 mm
in diameter) from the Van de Graaff accelerator
directed perpendicularly to the sampleís surface. In
order to get high quality X-ray characteristic spec-
tra, the acquisition time for measuring each sample
was set to 20 min. In every series 14 samples togeth-
er with 2 standards (IAEA H-8 Horse Kidney and
National Standards & Technology Standard
Reference Material 1577b Bovine Liver) were
mounted in the PIXE chamber. The standard materi-
als were used for energy calibration and determina-
tion of the trace elementsí concentration levels. All
the emitted X-ray quanta were detected with Si-Li
detector with the energy resolution of 190 eV for the
5.9 keV line. The normalization was performed
based on simultaneously detected spectra of back-
scattered protons. Both the X-rays and back-scat-
tered protons were recorded using Computer
Automated Measurement and Control (CAMAC)
electronic system. All the acquired spectra were
analyzed with GupixWin ver. 2.0 software. All
results, showing the level of metalsí concentration
in the ratsí pancreas, are presented as ëbox-and-
whiskerí plots showing median, lower and upper
quartiles (box) and the farthest data (whiskers). The
statistical calculations were performed using
Statistica 7.1 program. Differences between the
studied rat groups were estimated with the use of a
non-parametric Kruskal-Wallis test that enables to
compare three or more unpaired groups. Results
with p level below 0.05 were considered statistical-
ly significant (p < 0.05).
RESULTS
Vanadium
The level of vanadium in pancreas of diabetic
not-treated rats (D) and insulin-injected diabetic
ones (Di) was in the range from 0.25 ± 0.06 to 0.33
± 0.05 mg/kg of dry tissue. Similar data were report-
ed by Frank et al. (31). In pancreas of vanadium
compounds treated rats (Di1ñDi5) the concentration
of this element increased about 6 times as compared
to the diabetic control groups D and about 4ñ5 times
as compared to Di group, regardless of the chemical
structure of the compound and oxidation state of
vanadium (Fig. 1). This observation is similar to the
data presented by Cremer et al. (32) where the rats
were treated with an 48V isotope complex. The total
absorption of vanadium after oral administration of
the tested complexes was not calculated, however, it
is widely known that the level of V measured in
intestinal system equals roughly to ten percent of an
administered dose, and such a level of vanadium
uptake was assumed in the presented study (33). The
vanadium concentration in pancreas of vanadium-
treated ratsí ranged from 1.21 ± 0.27 to 1.69 ± 0.09
mg/kg of dry tissue. The lowest concentration
growth of vanadium was observed in the pancreas of
animals treated with complex 4, and the largest ñ
with complex 5. Both of the compounds have the
same vanadium oxidation state (IV) but different
ligands. The changes of the vanadium content in
pancreas of rats supplemented with compound 5
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were statistically significantly different in compari-
son to group D and Di (p < 0.05). 
It is known that the presence of metal adminis-
tration can influence the level of other metals such
as iron, copper, zinc, manganese, calcium or potas-
sium (34). Therefore, the concentrations of these
metals in the pancreas have been determined in our
analysis. 
Copper
The contents of copper determined in pancreas
for all the tested groups are presented in Fig. 2. The
application of insulin (group Di) caused the largest
decrease in the level of copper (50.72 ± 12.63 mg/
kg of dry tissue). Applying vanadium complexes
increased the Cu level in comparison to the Di
group. Statistically significant growth of the con-
centration of this element occurred for the complex
1, including the vanadium (V) and ligands bipyri-
dine (Di 1), and the complex 4 (Di 4) with vanadi-
um (IV) and ligands phenyls (82.50 ± 11.03 and
81.34 ± 26.95 mg/ kg of dry tissue, respectively).
Manganese
In case of the animals fed with the addition of
vanadium complexes 1, 4 and 5, the concentration of
manganese in the pancreas was reduced in compari-
son to the quantity of this microelement in the
groups D and Di (Fig. 3). The twofold decrease of
the manganese concentration was observed only in
Figure 1. Vanadium level in the study rat groups: (diabetic control rats (D), diabetic rats with insulin (Di), diabetic rats with insulin and
tested complexes (Di 1- Na[VO(O2)2(2,2í-bpy)] ï 8 H2O, Di2- Na[VO(O2)2(1,10í-phen)] ï 5 H2O , Di3- Na[VO(O2)2(4,4í-Me-2,2í-bpy)] ï
8 H2O, Di4- [VO(SO4)(1,10í-phen)] ï 2 H2O, Di5- [VO(SO4)(2,2í-bpy)] ï H2O)
Figure 2. Copper level in animal groups: (diabetic control rats (D), diabetic rats with insulin (Di), diabetic rats with insulin and tested com-
plexes (Di 1- Na[VO(O2)2(2,2í-bpy)] ï 8 H2O, Di2- Na[VO(O2)2(1,10í-phen)] ï 5 H2O , Di3- Na[VO(O2)2(4,4í-Me-2,2í-bpy)] ï 8 H2O, Di4-
[VO(SO4)(1,10í-phen)] ï 2 H2O, Di5- [VO(SO4)(2,2í-bpy)] ï H2O) 
Effects of vanadium complexes supplementation on... 587
case of the complex 1 (p < 0.05), while complexes 4
and 5 reduced the Mn quantity imperceptibly. The
influence of complexes 2 and 3 on the Mn concen-
tration in the pancreas was not observed.
Potassium
The concentration of potassium in the pancreas
of the rats (Fig. 4), which were treated with vanadium
complex 3 (16.32 ± 5.06 g/kg) increased in compari-
son to the animals from the group D (10.16 ± 3.27
g/kg) and Di (11.19 ± 2.17 g/kg), and the increase
was statistically significant (p < 0.05). Organic com-
plex of vanadium including methylbipyridine deriva-
tive (complex 3) raised the level of potassium in the
pancreas in comparison to the complex including
only bipyridine as a ligand (complex 1), and the result
was statistically significant (p < 0.05). 
The degree of the vanadium oxidation state
essentially influenced the concentration of potassi-
um in the pancreas. In case of vanadium complexes
at the IV oxidation level (complex 4 and 5), a
decrease in the potassium concentration in the pan-
creas was observed. The lowest potassium concen-
tration occurred in group Di 4 (7.16 ± 1.88 g/kg). A
decrease in potassium concentration in the pancreas
in case of the Di 4 and Di5 groups in comparison to
D and Di group, was observed but it was not statis-
tically significant.
Iron
The highest concentration of the iron in the
pancreas was observed in the diabetic control group
(317.0 ± 112.9 mg/kg of dry tissue) (Fig. 5). After
the injection of insulin in the Di group, the concen-
Figure 3. Manganese level in animal groups: (diabetic control rats (D), diabetic rats with insulin (Di), diabetic rats with insulin and tested
complexes (Di 1- Na[VO(O2)2(2,2í-bpy)] ï 8 H2O, Di2- Na[VO(O2)2(1,10í-phen)] ï 5 H2O , Di3- Na[VO(O2)2(4,4í-Me-2,2í-bpy)] ï 8 H2O,
Di4- [VO(SO4)(1,10í-phen)] ï 2 H2O, Di5- [VO(SO4)(2,2í-bpy)] ï H2O) 
Figure 4. Potassium level in animal groups: (diabetic control rats (D), diabetic rats with insulin (Di), diabetic rats with insulin and tested
complexes (Di 1- Na[VO(O2)2(2,2í-bpy)] ï 8 H2O, Di2- Na[VO(O2)2(1,10í-phen)] ï 5 H2O , Di3- Na[VO(O2)2(4,4í-Me-2,2í-bpy)] ï 8 H2O,
Di4- [VO(SO4)(1,10í-phen)] ï 2 H2O, Di5- [VO(SO4)(2,2í-bpy)] ï H2O)
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tration of this element dropped twice as compared to
the D group. Vanadium complexes 1, 3, 4 and 5
reduced the concentration of Fe to a statistically sig-
nificant degree in comparison to the groups Di (p <
0.05) and D (p < 0.05). It was also observed that
complexes 2 and 3 had not influenced the change of
the concentration of Fe in comparison to the Di
group.
Zinc
As shown in Fig. 6, zinc concentration was the
lowest in the D control group (19.83 ± 3.28 mg/kg),
not treated with vanadium. In the diabetic group
with insulin administration (Di), Zn concentration
was also very low (22.06 ± 33.47 mg/kg). In all the
vanadium-treated animal groups, the Zn concentra-
tion increased and the level was dependent on the
type of vanadium complexes used. It was statistical-
ly significant and 2 up to 6 times higher in compar-
ison to the diabetic group D and Di. Zn concentra-
tion was the highest in the pancreas of Di 1 and Di
2 animal groups (110.77 ± 13.74 mg/kg and 84.67 ±
16.34 mg/kg, respectively). In the Di 5 group, the
increase of Zn concentration was the lowest for
vanadium-treated rats (41.08 ± 17.28 mg/kg) but
still about two times higher in comparison to the
diabetic groups (D and Di), not treated with vanadi-
um. After both vanadium compounds 3 and 4
administration similar zinc concentration in the pan-
creas (64.59 ± 8.66 mg/kg and 63.36 ± 8.42 mg/kg,
respectively) was observed.
Calcium 
As shown in Fig 7, calcium concentration in
the pancreas was higher in the animals treated by the
vanadium complexes 3 and 5 (Di 3 and Di 5, respec-
Figure 5. Iron level in the study animal groups: (diabetic control rats (D), diabetic rats with insulin (Di), diabetic rats with insulin and test-
ed complexes (Di 1- Na[VO(O2)2(2,2í-bpy)] ï 8 H2O, Di2- Na[VO(O2)2(1,10í-phen)] ï 5 H2O , Di3- Na[VO(O2)2(4,4í-Me-2,2í-bpy)] ï 8
H2O, Di4- [VO(SO4)(1,10í-phen)] ï 2 H2O, Di5- [VO(SO4)(2,2í-bpy)] ï H2O) 
Figure 6. Zinc level in animal groups: (diabetic control rats (D), diabetic rats with insulin (Di), diabetic rats with insulin and tested com-
plexes (Di 1- Na[VO(O2)2(2,2í-bpy)] ï 8 H2O, Di2- Na[VO(O2)2(1,10í-phen)] ï 5 H2O , Di3- Na[VO(O2)2(4,4í-Me-2,2í-bpy)] ï 8 H2O, Di4-
[VO(SO4)(1,10í-phen)] ï 2 H2O, Di5- [VO(SO4)(2,2í-bpy)] ï H2O)
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tively, 204.3 ± 177.8 mg/kg, 219.2 ± 39/6 mg/kg,
210.5 mg/kg) than in the D group of diabetic rats
(172.3 ± 74.8 mg/kg), not treated with vanadium,
and the Di group (168.3 ± 57.7 mg/kg). Vanadium
(V) with bipyridine ligand (Di 1) treatment reduced
calcium concentration in the pancreas in a statisti-
cally significant way in comparison to the effect of
complex 3 and 5 and without statistical significance
in comparison to the pancreas of not diabetic rats not
treated with vanadium. Changes in the group Di 4
with vanadium (IV) with phenyl ligand in compari-
son to the diabetic not treated animals were not
observed. 
Complex 1 in comparison to the others vanadi-
um complexes had the strongest influence on the Cu,
Mn and Zn concentration and also an essential effect
on Fe concentration in the pancreas and at the same
time it had the weakest influence on the calcium, and
potassium concentration. Complex 2 showed a
strong influence on zinc concentration and mostly
non influence on other elementsí concentration as
compared to the Di group, however a decrease in
iron concentration as compared to the D group was
visible. Complex 3 had a substantial influence on
zinc and potassium concentration in the pancreas. All
the three tested complexes (groups Di1ñDi3) con-
tained vanadium (V) and different ligands. The influ-
ence on the measured metal concentration in pan-
creas is associated not only with the vanadium oxi-
dation state but also with the type of used ligands.
Complexes 4 and 5 contained both vanadium (IV).
Complex 4 caused more significant decrease on the
potassium and iron concentrations while complex 5
on zinc concentration in the pancreas. 
DISCUSSION
It has been shown that vanadium possesses
anti-diabetic activity and that it can be used as a
potential therapeutic agent in diabetes treatment in
several diabetic models (23). Simultaneously, sup-
plementation of this metal can influence the levels
of other metals in tissues and also indirectly, meta-
bolic parametersí such as enzymatic activity (35).
Scientific investigations showed that vanadium has
insulin mimetic properties and the ability of enhance
the effect of insulin (22, 35). Moreover, vanadium
can inhibit degradation of ligand-receptor complex
in lysosomes in different types of cells (36). 
Manganese is necessary for the metabolism of
vitamin B1 and vitamin E. It activates some
enzymes, takes part in the process of energy produc-
tion, synthesis of glycogen as well as urea. During
vanadium treatment, the changes of manganese con-
centration in ratsí pancreas were not significant.
This may suggest a minor influence of the tested
vanadium complexes on the functions regulated by
manganese in the pancreas. On the other hand, the
ratio of manganese to other elements concentrations
can affect the activity of some enzymes in pancreas.
Therefore, the influence of vanadium on manganese
level in pancreas and its possible effects should be
further studied. Enzymes activated by manganese in
pancreas and also possibly in other organs can be
useful in the elimination of oxidative stress in
patients with diabetes.
The increased potassium concentration may
suggest hyperkalemia, which is usually the result of
handicapped dismissing of potassium with urine and
Figure 7. Calcium level in animal groups: (diabetic control rats (D), diabetic rats with insulin (Di), diabetic rats with insulin and tested
complexes (Di 1- Na[VO(O2)2(2,2í-bpy)] ï 8 H2O, Di2- Na[VO(O2)2(1,10í-phen)] ï 5 H2O , Di3- Na[VO(O2)2(4,4í-Me-2,2í-bpy)] ï 8 H2O,
Di4- [VO(SO4)(1,10í-phen)] ï 2 H2O, Di5- [VO(SO4)(2,2í-bpy)] ï H2O) 
590 MIROS£AW KROåNIAK et al.
excessive freeing of potassium from cells. This
observation is associated only with the vanadium
complex 3 with vanadium (V) and methylbipyridine
ligand. 
Iron is a component of organic biomolecules
like: porphyrin, hemoglobin and myoglobin. It also
occurs in active sites of some enzymes. The concen-
tration of iron in the serum depends on absorption in
the alimentary line. The highest concentration of
iron is found in the intestines, the spleen (23) and the
bone marrow. The decrease of the iron concentra-
tion causes, among others, a chronic failure of kid-
neys and/or the shortage of C vitamin absorption. In
diabetic rats, not treated with insulin, the iron con-
centration was the highest. The administration of
insulin decreases the concentration of that element
in pancreas. This also confirms the insulin-mimetic
action of vanadium in diabetes. The untreated dia-
betes and biochemical changes associated with this
illness probably increase the iron concentration in
pancreas tissue. This observation needs to be con-
firmed by additional investigation. Administration
of insulin and/or vanadium caused the decrease of
the copper level in pancreas. The tested vanadium
complexes showed a similar influence on the level
of iron in pancreas. However, the influence differed
depending on the type of the vanadium complex
used. In groups Di 1, Di 4 and Di 5 in comparison to
the Di 2 and Di 3 the decrease of iron level was
greater. Surprisingly, thereís no clear trend of such
influence. Complex 1 as compared to 4 and 5 dif-
fered in oxidation state (V vs. IV) while complex 4
differed in ligand environment as compared to com-
plex 1 and 5. Additionally, the less significant
decrease in Fe concentration in group Di2 and Di3
could be related to vanadium oxidation state (V) but
this observation is in opposite to the influence of
complex 1, which was also vanadium (V) compo-
nent. 
At the molecular and cellular level, zinc (Zn) is
intimately involved in the insulin synthesis, secre-
tion and signalling, and thus, in the subsequent
effect of insulin on metabolism. Various clinical and
epidemiological studies suggest that reduced Zn sta-
tus is associated with diabetes (37, 38). The results
of presented study support this observation and
statement. The induced diabetes reduced zinc con-
centration in the pancreas of not treated animals.
Pancreas is the site of high Zn turnover and one
of the few organs that show reduced Zn concentration
during Zn deficiency (39). Reduced pancreatic Zn
concentrations have been reported in genetic mouse
models of Type 2 diabetes, ob/ob (mutation in ob
(leptin) gene and db/db (mutation in leptin receptor)
mice (40ñ42) and GK rats (Type 2 model produced
by selective breeding of rats with glucose intolerance)
(43) as compared to the non-diabetic ones.
Although a lot of effort has been placed on
studying Zn and pancreas, the consequences of
reduced pancreatic concentrations of other minerals
(e.g., Fe, Mn and Mg in GK rats) in co-action with
Zn have not been explored (42). Adequate levels of
pancreatic Zn may also be crucial to provide antiox-
idant protection, given that oxidative stress is a fac-
tor of tissue damage in Type 1 and Type 2 diabetes
and it is associated with complications occurring in
this disease (44, 45). Compared to several other tis-
sues, β-cells have lower levels of antioxidant
defense components and are susceptible to oxidative
damage (46ñ48). Zinc contributes to antioxidant
defense as a component of CuZn superoxide dismu-
tase (CuZnSOD) and metallothionein (MT).
Calcium level in different investigated groups
has not changed statistically and it is difficult to dis-
cuss the mutual relationship between the diabetes
insulin and the tested vanadium complexes.
This investigation showed that diabetes and itsí
treatment has an influence on the elemental level
measured in pancreas. Pancreas, being very impor-
tant organ in the diabetes control, is responsible for
the glucose level changes by insulin secretion
response. The investigated changes in the trace ele-
mentsí level were mostly perceptible for zinc and
iron. Zinc plays an important role in the physiologi-
cal function of pancreas. The animal group with dia-
betes induced by STZ had significantly lowered zinc
level in comparison to the vanadium-treated diabet-
ic groups. Vanadium stimulates the activity of
adenylate cyclase (CA), phospholipase C (PLC) and
phospholipase A2 (PLA2) (47). This action results in
the increased concentration of the secondary trans-
mitters, such as cAMP, IP3, DAG and also arachidic
acid. The increase of IP3 and arachidic acid level
caused an increase of the level of Ca2+ ions. It is pos-
sible that all these mechanisms participate also in
the zinc level elevation in pancreas. All the effects
associated with an anti-diabetic activity of vanadium
are not only the results of the insulin mimetic sig-
nalling pathway but also of the zinc concentration
protection, especially in pancreas. Zinc is an ele-
ment, which is known to have a protective activity in
the Type 2 diabetes. Such an observation is reported
for the first time in the literature. Therefore, it is not
possible to discuss it with the results of other
researchers.
Currently, the mutual interaction between
vanadium and zinc in pancreas remains unknown.
Better understanding of their interaction may offer
Effects of vanadium complexes supplementation on... 591
another possibility of increasing the understanding
of diabetes mechanisms and possible procedures for
treatment of that disease. 
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